A new narrative review argues that conflicting CDKN3 findings across cancers reflect incompatible evidence types, not a true ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results